Critical reviews in oncology/hematology最新文献

{"title":"Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review","authors":"L.F. van Schaik ,&nbsp;E.G. Engelhardt ,&nbsp;E.A. Wilthagen ,&nbsp;N. Steeghs ,&nbsp;A. Fernández Coves ,&nbsp;M.A. Joore ,&nbsp;W.H. van Harten ,&nbsp;V.P. Retèl","doi":"10.1016/j.critrevonc.2024.104441","DOIUrl":"10.1016/j.critrevonc.2024.104441","url":null,"abstract":"<div><p>Comprehensive Genomic Profiling (CGP) allows for the identification of many targets. Reimbursement decision-making is, however, challenging because besides the health benefits of on-label treatments and costs, other factors related to diagnostic and treatment pathways may also play a role. The aim of this study was to identify which other factors are relevant for the technology assessment of CGP and to summarize the available evidence for these factors. After a scoping search and two expert sessions, five factors were identified: feasibility, test journey, wider implications of diagnostic results, organisation of laboratories, and “scientific spillover”. Subsequently, a systematic search identified 83 studies collecting mainly evidence for the factors “test journey” and “wider implications of diagnostic results”. Its nature was, however, of limited value for decision-making. We recommend the use of comparative strategies, uniformity in outcome definitions, and the inclusion of a comprehensive set of factors in future evidence generation.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"202 ","pages":"Article 104441"},"PeriodicalIF":5.5,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related quality of life with comprehensive geriatric assessment guided care versus usual care in older adults with cancer: A systematic review and meta-analysis of randomized trials","authors":"Zhi Xuan Ng ,&nbsp;Pooja Handa ,&nbsp;Huili Zheng ,&nbsp;Matthew Zhixuan Chen ,&nbsp;Yu Yang Soon ,&nbsp;Prunella Blinman ,&nbsp;Martin Stockler ,&nbsp;Francis Ho","doi":"10.1016/j.critrevonc.2024.104442","DOIUrl":"10.1016/j.critrevonc.2024.104442","url":null,"abstract":"<div><h3>Background</h3><p>To evaluate if comprehensive geriatric assessment (CGA)-guided care improves health-related quality of life (HRQL) in older adults with cancer compared to usual care.</p></div><div><h3>Methods</h3><p>Relevant randomized controlled trials (RCTs) were identified through biomedical databases. Meta-analyses using DerSimonian-Laird model summarized the difference in the mean change of HRQL scores from baseline across various time points, with evidence certainty assessed by the GRADE tool. Logistic regression via generalized estimating equations analyzed predictors of HRQL improvement.</p></div><div><h3>Results</h3><p>Potential improvement in the global HRQL score by CGA-guided care at 3 months (Cohen’s d 0.27, 95 % CI −0.03–0.58, moderate certainty), could not be excluded. Larger RCTs or those mandating CGA before initiating anti-cancer treatment were predictors of improved HRQL.</p></div><div><h3>Conclusion</h3><p>The effects of CGA-guided care on HRQL were variable. Larger RCTs and those mandating pre-treatment CGA tended to report improved HRQL.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"201 ","pages":"Article 104442"},"PeriodicalIF":5.5,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success","authors":"Lorenzo Belluomini ,&nbsp;Alice Avancini ,&nbsp;Marco Sposito ,&nbsp;Letizia Pontolillo ,&nbsp;Daniela Tregnago ,&nbsp;Ilaria Trestini ,&nbsp;Jessica Insolda ,&nbsp;Luisa Carbognin ,&nbsp;Michele Milella ,&nbsp;Emilio Bria ,&nbsp;Sara Pilotto","doi":"10.1016/j.critrevonc.2024.104444","DOIUrl":"10.1016/j.critrevonc.2024.104444","url":null,"abstract":"<div><p>Over the years, advancements in antiemetic drugs have improved chemotherapy-induced nausea and vomiting (CINV) control. However, despite the antiemetics therapies, in a relevant number of adult patients (∼30 %), CINV is still persistent, leading to several complications, such as electrolyte imbalances, anorexia, and treatment discontinuation. Supportive care interventions have gained credibility in cancer care, helping to improve patients' psycho-physical condition, quality of life, and managing symptoms, including CINV. Physical exercise and tailored nutritional counseling have demonstrated benefits in reducing the severity of nausea and vomiting. Psychological intervention has been postulated as a key approach in controlling anticipatory nausea/vomiting, as well as acupuncture/acupressure has been shown to decrease nausea and vomiting after chemotherapy treatments. In the current review, we aim to provide a clinical update on current prophylactic and delayed antiemetic guidelines for CINV and an overview of the non-pharmacological interventions tested for alleviating CINV in patients with cancer.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"201 ","pages":"Article 104444"},"PeriodicalIF":5.5,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824001872/pdfft?md5=ba1c560701d84a8a6cbe35c71570b9be&pid=1-s2.0-S1040842824001872-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative imaging predictors of tumor progression and pseudoprogression: A systematic review","authors":"","doi":"10.1016/j.critrevonc.2024.104445","DOIUrl":"10.1016/j.critrevonc.2024.104445","url":null,"abstract":"<div><p>In high-grade gliomas, pseudoprogression after radiation treatment might dramatically impact patient’s management. We searched for perioperative imaging predictors of pseudoprogression in high-grade gliomas according to PRISMA guidelines, using MEDLINE/Pubmed and Embase (until January 2024).</p><p>Study design, sample size, setting, diagnostic gold standard, imaging modalities and contrasts, and differences among variables or measures of diagnostic accuracy were recorded. Study quality was assessed through the QUADAS-2 tool.</p><p>Twelve studies (11 with MRI, one with PET; 1058 patients) were reviewed. Most studies used a retrospective design (9/12), and structural MRI (7/12). Studies were heterogeneous in metrics and diagnostic reference standards; patient selection bias was a frequent concern. Pseudoprogression and progression showed some significant group differences in perioperative imaging metrics, although often with substantial overlap. Radiomics showed moderate accuracy but requires further validation.</p><p>Current literature is scarce and limited by methodological concerns, highlighting the need of new predictors and multiparametric approaches.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"202 ","pages":"Article 104445"},"PeriodicalIF":5.5,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824001884/pdfft?md5=3be3ad78762e5022f47190cbf28a37b1&pid=1-s2.0-S1040842824001884-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting ferroptosis suppressor protein 1 in cancer therapy: Implications and perspectives, with emphasis on head and neck cancer","authors":"","doi":"10.1016/j.critrevonc.2024.104440","DOIUrl":"10.1016/j.critrevonc.2024.104440","url":null,"abstract":"<div><p>The diverse functions of ferroptosis suppressor protein 1 (FSP1/AIFM2) in cancer have positioned it as a promising therapeutic target across various malignancies, including head and neck cancer (HNC). Initially characterized as a potential tumor suppressor due to its involvement in apoptosis and ferroptosis, recent studies have revealed its complex role in tumor growth, metabolism, and therapy resistance. Pharmacological inhibition of FSP1 shows potential in sensitizing cancer cells to ferroptosis and overcoming resistance to conventional therapies, offering new avenues for precision medicine approaches. Identifying novel FSP1 inhibitors and their synergistic effects with existing therapies presents exciting opportunities for therapeutic development. However, translating preclinical findings into clinical practice requires the refinement of FSP1 inhibitors, robust biomarkers for patient stratification, and further investigations into the molecular mechanisms underlying FSP1-mediated therapy resistance. Integrating FSP1-targeted therapies into comprehensive treatment regimens holds promise for improving outcomes in cancer patients and advancing the field of precision oncology.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"202 ","pages":"Article 104440"},"PeriodicalIF":5.5,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of hematological and neurological expressed 1 (HN1) in human cancers","authors":"Huangcan Li ,&nbsp;Simiao Fan ,&nbsp;Zhongqin Gong,&nbsp;Jason Ying Kuen Chan,&nbsp;Michael Chi Fai Tong,&nbsp;George Gong Chen","doi":"10.1016/j.critrevonc.2024.104446","DOIUrl":"10.1016/j.critrevonc.2024.104446","url":null,"abstract":"<div><p>Hematological and neurological expressed 1 (HN1), also known as Jupiter microtubule associated homolog 1 (JPT1), is a highly conserved protein with widespread expression in various tissues. Ectopic elevation of HN1 has been observed in multiple cancers, highlighting its role in tumorigenesis and progression. Both proteomics and transcriptomics reveal that HN1 is closely associated with severe disease progression, poor prognostic and shorter overall survival. HN1's involvement in cancer cell proliferation and metastasis has been extensively investigated. Overexpression of HN1 is associated with increased tumor growth and disease progression, while its depletion leads to cell cycle arrest and apoptosis. The pivotal role of HN1 in cancer progression, particularly in proliferation, migration, and invasion, underscores its significance in cancer metastasis. Validation of the efficacy and safety of HN1 inhibition, along with the development of diagnostic methods to determine HN1 expression levels in patients, is essential for the translation of HN1-targeted therapies into clinical practice. Overall, HN1 emerges as a valuable prognostic marker and therapeutic target in cancer, and further investigations hold the potential to improve patient outcomes by impeding metastasis and enhancing treatment strategies.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"201 ","pages":"Article 104446"},"PeriodicalIF":5.5,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multigenic panels in breast cancer: clinical utility and management of patients with pathogenic variants other than BRCA1/2","authors":"Alessandra Fabi ,&nbsp;Laura Cortesi ,&nbsp;Simona Duranti ,&nbsp;Emanuela Lucci Cordisco ,&nbsp;Alba Di Leone ,&nbsp;Daniela Terribile ,&nbsp;Ida Paris ,&nbsp;Antonio Giulio de Belvis ,&nbsp;Armando Orlandi ,&nbsp;Fabio Marazzi ,&nbsp;Margherita Muratore ,&nbsp;Giorgia Garganese ,&nbsp;Paola Fuso ,&nbsp;Filippo Paoletti ,&nbsp;Rossella Dell’Aquila ,&nbsp;Angelo Minucci ,&nbsp;Giovanni Scambia ,&nbsp;G. Franceschini ,&nbsp;R. Masetti ,&nbsp;Maurizio Genuardi","doi":"10.1016/j.critrevonc.2024.104431","DOIUrl":"10.1016/j.critrevonc.2024.104431","url":null,"abstract":"<div><p>Multigene panels can analyze high and moderate/intermediate penetrance genes that predispose to breast cancer (BC), providing an opportunity to identify at-risk individuals within affected families. However, considering the complexity of different pathogenic variants and correlated clinical manifestations, a multidisciplinary team is needed to effectively manage BC. A classification of pathogenic variants included in multigene panels was presented in this narrative review to evaluate their clinical utility in BC. Clinical management was discussed for each category and focused on BC, including available evidence regarding the multidisciplinary and integrated management of patients with BC. The integration of both genetic testing and counseling is required for customized decisions in therapeutic strategies and preventative initiatives, as well as for a defined multidisciplinary approach, considering the continuous evolution of guidelines and research in the field.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"201 ","pages":"Article 104431"},"PeriodicalIF":5.5,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141560504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic vulnerabilities in cancer: A new therapeutic strategy","authors":"","doi":"10.1016/j.critrevonc.2024.104438","DOIUrl":"10.1016/j.critrevonc.2024.104438","url":null,"abstract":"<div><p>Cancer metabolism is now a key area for therapeutic intervention, targeting unique metabolic reprogramming crucial for tumor growth and survival. This article reviews the therapeutic potential of addressing metabolic vulnerabilities through glycolysis and glutaminase inhibitors, which disrupt cancer cell metabolism. Challenges such as tumor heterogeneity and adaptive resistance are discussed, with strategies including personalized medicine and predictive biomarkers to enhance treatment efficacy. Additionally, integrating diet and lifestyle changes with metabolic targeting underscores a holistic approach to improving therapy outcomes. The article also examines the benefits of incorporating these strategies into standard care, highlighting the potential for more tailored, safer treatments. In conclusion, exploiting metabolic vulnerabilities promises a new era in oncology, positioning metabolic targeting at the forefront of personalized cancer therapy and transforming patient care.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"201 ","pages":"Article 104438"},"PeriodicalIF":5.5,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141560503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Faecal immunochemical tests can improve colonoscopy triage in patients with iron deficiency: A systematic review and meta-analysis","authors":"Jennifer Pham ,&nbsp;Geraldine Laven-Law ,&nbsp;Erin L. Symonds ,&nbsp;Molla M. Wassie ,&nbsp;Charles Cock ,&nbsp;Jean M. Winter","doi":"10.1016/j.critrevonc.2024.104439","DOIUrl":"10.1016/j.critrevonc.2024.104439","url":null,"abstract":"<div><h3>Background</h3><p>Use of the faecal immunochemical test (FIT) to triage patients with iron deficiency (ID) for colonoscopy due to suspected colorectal cancer (CRC) may improve distribution of colonoscopic resources. We reviewed the diagnostic performance of FIT for detecting advanced colorectal neoplasia, including CRC and advanced pre-cancerous neoplasia (APCN), in patients with ID, with or without anaemia.</p></div><div><h3>Methods</h3><p>We performed a systematic review of three databases for studies comprising of patients with ID, with or without anaemia, completing a quantitative FIT within six months prior to colonoscopy, where test performance was compared against the reference standard colonoscopy. Random effects meta-analyses determined the diagnostic performance of FIT for advanced colorectal neoplasia.</p></div><div><h3>Results</h3><p>Nine studies were included on a total of n=1761 patients with ID, reporting FIT positivity thresholds between 4–150 µg haemoglobin/g faeces. Only one study included a non-anaemic ID (NAID) cohort. FIT detected CRC and APCN in ID patients with 90.7 % and 49.3 % sensitivity, and 81.0 % and 82.4 % specificity, respectively. FIT was 88.0 % sensitive and 83.4 % specific for CRC in patients with ID anaemia at a FIT positivity threshold of 10 µg haemoglobin/g faeces.</p></div><div><h3>Conclusions</h3><p>FIT shows high sensitivity for advanced colorectal neoplasia and may be used to triage those with ID anaemia where colonoscopic resources are limited, enabling those at higher risk of CRC to be prioritised for colonoscopy. There is a need for further research investigating the diagnostic performance of FIT in NAID patients.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"201 ","pages":"Article 104439"},"PeriodicalIF":5.5,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824001823/pdfft?md5=ac5a5330855ecad38078ae828e6a08b6&pid=1-s2.0-S1040842824001823-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141560501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneous pathogenesis of melanoma: BRAF mutations and beyond","authors":"Maria Colombino ,&nbsp;Milena Casula ,&nbsp;Panagiotis Paliogiannis ,&nbsp;Antonella Manca ,&nbsp;Maria Cristina Sini ,&nbsp;Marina Pisano ,&nbsp;Davide Adriano Santeufemia ,&nbsp;Antonio Cossu ,&nbsp;Giuseppe Palmieri","doi":"10.1016/j.critrevonc.2024.104435","DOIUrl":"10.1016/j.critrevonc.2024.104435","url":null,"abstract":"<div><p>Melanoma pathogenesis, conventionally perceived as a linear accumulation of molecular changes, discloses substantial heterogeneity driven by non-linear biological processes, including the direct transformation of melanocyte stem cells. This heterogeneity manifests in diverse biological phenotypes and developmental states, influencing variable responses to treatments. Unveiling the aberrant mechanisms steering melanoma initiation, progression, and metastasis is imperative. Beyond mutations in oncogenic and tumor suppressor genes, the involvement of distinct molecular pathways assumes a pivotal role in melanoma pathogenesis. Ultraviolet (UV) radiations, a principal factor in melanoma etiology, categorizes melanomas based on cumulative sun damage (CSD). The genomic landscape of lesions correlates with UV exposure, impacting mutational load and spectrum of mutations. The World Health Organization's 2018 classification underscores the interplay between sun exposure and genomic characteristics, distinguishing melanomas associated with CSD from those unrelated to CSD. The classification elucidates molecular features such as tumor mutational burden and copy number alterations associated with different melanoma subtypes. The significance of the mutated BRAF gene and its pathway, notably BRAFV600 variants, in melanoma is paramount. BRAF mutations, prevalent across diverse cancer types, present therapeutic avenues, with clinical trials validating the efficacy of targeted therapies and immunotherapy. Additional driver mutations in oncogenes further characterize specific melanoma pathways, impacting tumor behavior. While histopathological examination remains pivotal, challenges persist in molecularly classifying melanocytic tumors. In this review, we went through all molecular characterization that aid in discriminating common and ambiguous lesions. Integration of highly sensitive molecular diagnostic tests into the diagnostic workflow becomes indispensable, particularly in instances where histology alone fails to achieve a conclusive diagnosis. A diagnostic algorithm based on different molecular features inferred by the various studies is here proposed.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"201 ","pages":"Article 104435"},"PeriodicalIF":5.5,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824001781/pdfft?md5=1a9885e2d0777eedc36903d2582511d7&pid=1-s2.0-S1040842824001781-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141560502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}